Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Impedimed Limited ( (AU:IPD) ) just unveiled an update.
ImpediMed Limited has announced a change in the director’s interest notice, highlighting a modification in the securities held by Director Ms. Janelle Delaney. As of January 31, 2025, Ms. Delaney acquired an additional 156,115 ordinary shares directly, as part of a compensation arrangement for director fees for the quarter ending December 2024. The adjustment reflects strategic financial management within the company, potentially strengthening its governance framework by aligning director incentives with shareholder interests.
More about Impedimed Limited
ImpediMed Limited operates in the medical technology industry, focusing on developing and providing advanced bioimpedance spectroscopy devices used primarily for the non-invasive assessment and monitoring of body composition and fluid status. The company targets healthcare markets, offering solutions for managing lymphedema and heart failure, among other conditions.
YTD Price Performance: -2.50%
Average Trading Volume: 31,879
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $69.19M
Find detailed analytics on IPD stock on TipRanks’ Stock Analysis page.
